Follow Our Live Coverage of COVID-19 Developments

Company Reaches $1.4 Billion Settlement in Opioid Treatment Investigation

Settlement the largest in U.S. history in a case involving an opioid medication

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, July 15, 2019 (HealthDay News) -- A drug company has reached a $1.4 billion settlement with the U.S. government over an investigation into the company's marketing and sales of a prescription drug used to treat opioid addiction.

From 2010 through 2014, the Reckitt Benckiser Group or its subsidiaries mishandled the marketing or improperly controlled the pricing of the drug Suboxone (buprenorphine and naloxone), government officials alleged, CNN reported. In a statement, Reckitt Benckiser said it has "has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct."

"Drug manufacturers marketing products to help opioid addicts are expected to do so honestly and responsibly," Jody Hunt, assistant attorney general in the Civil Division of the U.S. Justice Department, said in a department news release.

This settlement is the largest in U.S. history in a case involving an opioid medication, CNN reported.

CNN Article
More Information: DOJ

Last Updated: